Synribo is indicated for the treatment of adult patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI). This indication is based upon response rate. There are no trials verifying an improvement in disease-related symptoms or increased survival with SYNRIBO. SYNRIBO (omacetaxine mepesuccinate) for Injection Tablets should be administered under the supervision of a qualified physician experienced in the uses of cancer chemotherapeutic agents.

Where can I buy Synribo?

Indian Pharma Network (IPN) New Delhi, INDIA.

IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its presence PAN India with over 20 years of domain experience.

IPN helps patients, doctors and hospitals as a facilitator to import prescription medicine brand Synribo (omacetaxine mepesuccinate) for Injection on prescription and Import License in Patient's Name only.

For Synribo or (omacetaxine mepesuccinate) for Injection price in India.
Please contact +91 9811747774 or
Synribo (omacetaxine mepesuccinate) for Injection

Get In Touch

Facilitator under Patient Assistance Programs In India

For Indian Patients, doctors and hospitals Synribo (omacetaxine mepesuccinate) for Injection can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Dosage Forms and Strengths

Single-use vial containing 3.5 mg of omacetaxine mepesuccinate as a lyophilized powder. .


FDA Approval Summary

U.S. Food and Drug Administration Approval Summary: Omacetaxine Mepesuccinate as Treatment for Chronic Myeloid Leukemia